Some images has been designed using resources from Unsplash & Pixabay & Pexels & Freepik and some icons from Flaticon
跳到主要內容
全站搜尋
:::

賴峻毅 (Jiun-I Lai)

賴峻毅(Jiun-I Lai)圖 複診掛號 初診掛號

[簡介]

  • 學歷
    • 美國斯克里普斯研究所 博士 (2016)
    • 國立陽明大學 醫學系 醫學士 (2005)
  • 經歷
    現職：
    • 2018- 迄今 國立陽明交通大學 臨床醫學研究所 助理教授
    • 2019- 迄今 臺北榮民總醫院 腫瘤醫學部 腫瘤內科 主治醫師
    經歷：
    • 2017- 2019 臺北榮民總醫院 腫瘤醫學部藥物治療科 總醫師
    • 2016- 2017 衛福部金門醫院 主治醫師
    • 2010- 2016 美國斯克里普斯研究所 細胞分子生物所 博士學位進修
    • 2009- 2010 國立陽明大學附設醫院 主治醫師
    • 2006- 2009 臺北榮民總醫院 內科部 住院醫師訓練
  • 醫療專長
    1. 腫瘤內科學、乳癌, 泌尿系統癌症
  • 證照
    ECFMG/USMLE、腫瘤內科專科醫師、內科專科醫師、 乳房專科醫師、台灣癌症安寧緩和醫學會專科醫師

[著作]

PubMed

  1. Ting-I Lin, Yi-Ru Tseng, Min-Jyun Dong, Chih-Yi Lin, Wei-Ting Chung, Chun-Yu Liu, Yi-Fang Tsai, Chi-Cheng Huang, Ling-Ming Tseng, Ta-Chung Chao, Jiun-I Lai. HDAC inhibitors modulate Hippo pathway signaling in hormone-positive breast cancer. Clinical Epigenetics 2025 Feb 26;17(1):37.
  2. Lai JI, Jung KH, Shimizu C, Tiambeng ML, Tseng LM, Hsu DC, Ihm SY, Spiteri C, Tan EM, Qu S, Antill Y. Patients' and doctors' preferences in early-stage triple-negative breast cancer treatment in Asia-Pacific: a multi-territory discrete choice experiment using a cross-sectional survey. BMJ Open. 2025 Mar 3;15(3):e088505
  3. I-Wei Ho, Yi-Ru Tseng, Chun-Yu Liu, Yi-Fang Tsai, Chi-Cheng Huang, Ling-Ming Tseng, Ta-Chung Chao, Jiun-I Lai. Addition of bevacizumab to vinorelbine-platinum combination is efficacious in heavily pretreated HER2-negative metastatic breast cancer. J Cancer 2025; 16(5):1726-1735. doi:10.7150/jca.105199
  4. Kevin Kalinsky, Giampaolo Bianchini, Erika Hamilton, Stephanie L Graff, Kyong Hwa Park, Rinath Jeselsohn, Miguel Martin, Rachel M Layman, Sara A Hurvitz, Sarah Sammons, Peter A Kaufman, Montserrat Muñoz, Jiun-I Lai, Holly Knoderer, Cynthia Sandoval, Aarti R Chawla, Bastien Nguyen, Yanhong Zhou, Elizabeth Ravenberg, Lacey M Litchfield 14, Lillian Smyth, Seth A Wander. Abemaciclib Plus Fulvestrant in Advanced Breast Cancer Following Progression on CDK4/6 Inhibition: Results from the Phase III postMONARCH Trial. J Clin Oncol. 2024 Dec 18: JCO2402086. doi: 10.1200/JCO-24-02086
  5. Jiun-I Lai, Yu-Ching Peng, Peter Mu-Hsin Chang, Yen-Hwa Chang, Hsiao-Jen Chung, Yi-Hsiu Huang, Tzu-Ping Lin, William J Huang, Tzu-Chun Wei, Tzu-Hao Huang, Chueh-Chuan Yen. Real world experience in treatment outcome and genomic insights for metastatic prostate neuroendocrine carcinoma. Journal of the Chinese Medical Association ():10.1097/JCMA.0000000000001209, January 17, 2025.
  6. Jiun-I Lai, Ting-Hao Kuo, Kuan-jung Huang, Laura Min Xuan Chai, Mei-Hsuan Lee, Chun-Yu Liu, Yi-Fang Tsai, Chi-Cheng Huang, Ling-Ming Tseng, Cheng-Chih Hsu, Ta-Chung Chao. Clinical and genotypic insights into higher prevalence of palbociclib associated neutropenia in Asian patients. The Oncologist. 2024 Apr 4;29(4):e455-e466
  7. Cheng HF, Tsai YF, Liu CY, Hsu CY, Lien PJ, Lin YS, Chao TC, Lai JI, Feng CJ, Chen YJ, Chen BF, Chiu JH, Tseng LM, Huang CC. Prevalence of BRCA1, BRCA2, and PALB2 genomic alterations among 924 Taiwanese breast cancer assays with tumor-only targeted sequencing: extended data analysis from the VGH-TAYLOR study. Breast Cancer Res. 2023 Dec 14;25(1):152
  8. Ho IW, Pan YL, Lai JI, Liu CY. Characteristics and outcome of systemic treatment for metastatic or unresectable thymic carcinoma: A single institution experience. Thorac Cancer. 2023 Dec 27.
  9. Jiun-I Lai, Ta-Chung Chao, Chun-Yu Liu, Chi-Cheng Huang, Ling-Ming Tseng. A Systemic Review of Taxanes and Their Side Effects in Metastatic Breast Cancer. Frontiers in Oncology, 2022 Oct 11;12:940239. doi: 10.3389/fonc.2022.940239.

  10. ChihYi Lin, Chung-Jen Yu, Chia-I Shen, Chun-Yu Liu, Ta-Chung Chao, Chi-Cheng Huang, Ling-Ming Tseng, Jiun-I Lai. IKZF3 amplification frequently occurs in HER2 positive breast cancer and is a potential therapeutic target. Medical Oncology, 2022 Sep 30;39(12):242. doi: 10.1007/s12032-022-01812-x.

  11. Chih-Yi Lin, Chung-Jen Yu, Chun-Yu Liu, Ta-Chung Chao, Chi-Cheng Huang, Ling-Ming Tseng, Jiun-I Lai. CDK4/6 inhibitors downregulate the ubiquitin conjugating enzymes UBE2C/S/T involved in the ubiquitin–proteasome pathway in ER+ breast cancer. Clinical and Translational Oncology 2022 Aug 2. doi: 10.1007/s12094-022-02881-0

  12. Tang CY, Hang JF, Hung YP, Chiu NC, Lai JI, Chen MH, Liu CY, Yang MH, Chao Y, Chang PM. A generational comparison for unfavorable cancer of unknown primary in a single institute over 20 years. Cancer Med. 2022 Jul 3. doi: 10.1002/cam4.4960

  13. Huang CC, Tsai YF, Liu CY, Lien PJ, Lin YS, Chao TC, Feng CJ, Chen YJ, Lai JI, Phan NN, Hsu CY, Chiu JH, Tseng LM. Prevalence of Tumor Genomic Alterations in Homologous Recombination Repair Genes Among Taiwanese Breast Cancers. Ann Surg Oncol. 2022 Jun;29(6):3578-3590 

  14. Lai JI, Tseng YJ, Chen MH, Huang CF, Chang PM. Clinical Perspective of FDA Approved Drugs With P-Glycoprotein Inhibition Activities for Potential Cancer Therapeutics. Front Oncol. 2020 Nov 16;10:561936

  15. Tan KT, Yeh CN, Chang YC, Cheng JH, Fang WL, Yeh YC, Wang YC, Hsu DS, Wu CE, Lai JI, Chang PM, Chen MH, Lu ML, Chen SJ, Chao Y, Hsiao M, Chen MH. PRKDC: new biomarker and drug target for checkpoint blockade immunotherapy. J Immunother Cancer. 2020 Mar;8(1):e000485

  16. Chang SC, Lai YC, Chang CY, Huang LK, Chen SJ, Tan KT, Yu PN, Lai JI. Concomitant Genetic Alterations are associated with worse clinical outcome in EGFR mutant NSCLC patients treated with tyrosine kinase inhibitors. (Corresponding Author) Transl Oncol. 2019 Aug 8;12(11):1425-1431. doi: 10.1016/j.tranon.2019.07.008.

  17. Jiun-I Lai, Abhinav K. Reddy, Justin Y. Newberg, Meagan Montesion, Peter Mu-Hsin Chang. High-grade salivary gland ductal carcinoma with unusual EGFR amplification responsive to afatinib. JCO Precis Oncol. 2019 Dec;3:1-5. doi: 10.1200/PO.19.00186.

  18. Chen MH, Chang SC, Lin PC, Yang SH, Lin CC, Lan YT, Lin HH, Lin CH, Lai JI, Liang WY, Lu ML, Yang MH, Chao Y. Combined Microsatellite Instability and Elevated Microsatellite Alterations at Selected Tetranucleotide Repeats (EMAST) Might Be a More Promising Immune Biomarker in Colorectal Cancer. Oncologist. 2019 Jul 10. pii: theoncologist.2019-0171. 

  19. Chiu, Yu-Hui, Lai, Jiun-I, Tseng, Chia-Ying,Wang, Shih-Hao,Li, Li-Hua,Kao, Wei-Fong,How, Chorng-Kuang ,Chang, Wen-Han ,Hsieh, Chin-Yi. Impact of angiotension I converting enzyme gene I/D polymorphism on running performance, lipid, and biochemical parameters in ultra-marathoners. (Co-first author) Medicine (Baltimore). 2019 Jul;98(29):e16476.

  20.  Jiun-I Lai, Daniel Nachun, Lina Petrosyan, Benjamin Throesch, Erica Campau, Fuying Gao, Kristin K Baldwin, Giovanni Coppola, Joel M. Gottesfeld, Elisabetta Soragni. Transcriptional profiling of isogenic Friedreich ataxia neurons and effect of an HDAC inhibitor on disease signatures. J Biol Chem. 2019 Feb 8;294(6):1846-1859. doi: 10.1074/jbc.RA118.006515.

  21. Chang SC, Lai JI, Lu MC, Lin KH, Wang WS, Lo SS, Lai YC. Reduction in the incidence of pneumonia in elderly patients after hip fracture surgery: An inpatient pulmonary rehabilitation program. Medicine (Baltimore). 2018 Aug;97(33):e11845

  22. Chang SC, Lai YC, Chen YC, Wang NK, Pan JN, Wang WS, Lai JI. (Corresponding Author) CBX3/heterochromatin protein 1 gamma is significantly upregulated in patients with non-small cell lung cancer. Asia-Pacific Journal of Clinical Oncology, 2017 Nov 10. doi: 10.1111/ajco.12820. 

  23. Lai JI, Lai YC, Chen YC, Wang NK, Pan JN, Wang WS, Chang SC. Clinical analysis of NSCLC patients reveals lack of association between EGFR mutation and TET1 downregulation. Cancer Gene Ther. 2017 Sep;24(9):373-380. doi: 10.1038/cgt.2017.26. 

  24. Lai JI, Leman LJ, Ku S, Vickers CJ, Olsen CA, Montero A, Ghadiri MR, Gottesfeld JM.Cyclic tetrapeptide HDAC inhibitors as potential therapeutics for spinal muscular atrophy: Screening with iPSC-derived neuronal cells. Bioorg Med Chem Lett. 2017 Aug 1;27(15):3289-3293. doi: 10.1016/j.bmcl.2017.06.027.

 

回到最上